Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Yu, Run ^a   Dhall, Deepti ^b   Nissen, Nicholas N ^a   Zhou, Cuiqi ^b   Ren, Song Guang ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON RECEPTOR; INSULIN; METHIONINE; PANCREAS POLYPEPTIDE; SOMATOSTATIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; MEN1 PROTEIN, MOUSE; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL AGGREGATION; CELL COMPOSITION; CELL STRUCTURE; CONTROLLED STUDY; DISEASE COURSE; ENZYME INHIBITION; HORMONE RELEASE; HUMAN; LIVER METASTASIS; MALE; MOLECULAR DYNAMICS; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET ALPHA CELL; PANCREAS TUMOR; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TUMOR DIAGNOSIS; TUMOR DIFFERENTIATION; ANIMAL; CELL DIFFERENTIATION; CELL SIZE; ENDOCRINE SYSTEM; GENETICS; HOMOZYGOTE; HYPERPLASIA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

MUS;

ANIMALS; CELL DIFFERENTIATION; CELL SIZE; ENDOCRINE SYSTEM; HOMOZYGOTE; HUMANS; HYPERPLASIA; MICE; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTORS, GLUCAGON;

EID: 80051494742     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023397     Document Type: Article

References (49)

1. Gromada J, Franklin I, Wollheim CB, (2007) Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28: 84-116.
2. Quesada I, Tudurí E, Ripoll C, Nadal A, (2008) Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol 199: 5-19.
3. Mayo KE, Miller LJ, Bataille D, Dalle S, Göke B, et al. (2003) International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55: 167-194.
4. Authier F, Desbuquois B, (2008) Glucagon receptors. Cell Mol Life Sci 65: 1880-1899.
5. Jiang G, Zhang BB, (2003) Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284: E671-E678.
6. Sloop KW, Michael MD, Moyers JS, (2005) Glucagon as a target for the treatment of Type 2 diabetes. Expert Opin Ther Targets 9: 593-600.
7. Ali S, Drucker DJ, (2009) Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab 296: E415-E421.
8. Petersen KF, Sullivan JT, (2001) Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44: 2018-2024.
9. Qureshi SA, Rios Candelore M, Xie D, Yang X, Tota LM, et al. (2004) A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 53: 3267-3273.
10. Winzell MS, Brand CL, Wierup N, Sidelmann UG, Sundler F, et al. (2007) Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. Diabetologia 50: 1453-1462.
11. Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, et al. (2004) Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 113: 1571-1581.
12. Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, et al. (2004) Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53: 410-417.
13. Sørensen H, Brand CL, Neschen S, Holst JJ, Fosgerau K, et al. (2006) Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 55: 2843-2848.
14. Yan H, Gu W, Yang J, Bi V, Shen Y, et al. (2009) Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. J Pharmacol Exp Ther 329: 102-111.
15. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD, (2002) Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290: 839-843.
16. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, et al. (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100: 1438-1443.
17. Vuguin PM, Kedees MH, Cui L, Guz Y, Gelling RW, et al. (2006) Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. Endocrinology 1470: 3995-4006.
18. Yu R, Nissen NN, Dhall D, Heaney A, (2008) Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas. Pancreas 36: 428-431.
19. Zhou C, Dhall D, Nissen NN, Chen C, Yu R, (2009) Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas 38: 941-946.
20. Yu R, Wawrowsky K, Zhou C, (2011) A natural inactivating mutant of human glucagon receptor exhibits multiple abnormalities in processing and signaling. Endocrinol Nutr 58: 258-266.
21. Oberg K, (2009) Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes 16: 72-78.
22. Antonello D, Gobbo S, Corbo V, Sipos B, Lemoine NR, et al. (2009) Pancreatology Update on the molecular pathogenesis of pancreatic tumors other than common ductal adenocarcinoma 9: 25-33.
23. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, et al. (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331: 1199-1203.
24. Corbo V, Dalai I, Scardoni M, Barbi S, Beghelli S, et al. (2010) MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer 17: 771-783.
25. Shen HC, He M, Powell A, Adem A, Lorang D, et al. (2009) Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. Cancer Res 69: 1858-1866.
26. Efrat S, Teitelman G, Anwar M, Ruggiero D, Hanahan D, (1988) Glucagon gene regulatory region directs oncoprotein expression to neurons and pancreatic alpha cells. Neuron 1: 605-613.
27. Rindi G, Efrat S, Ghatei MA, Bloom SR, Solcia E, et al. (1991) Glucagonomas of transgenic mice express a wide range of general neuroendocrine markers and bioactive peptides. Virchows Arch A Pathol Anat Histopathol 419: 115-129.
28. Lee YC, Asa SL, Drucker DJ, (1992) Glucagon gene 5′-flanking sequences direct expression of simian virus 40 large T antigen to the intestine, producing carcinoma of the large bowel in transgenic mice. J Biol Chem 267: 10705-10708.
29. Asa SL, Lee YC, Drucker DJ, (1996) Development of colonic and pancreatic endocrine tumours in mice expressing a glucagon-SV40 T antigen transgene. Virchows Arch 427: 595-606.
30. Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, et al. (2003) A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A 98: 1118-1123.
31. Bertolino P, Tong WM, Galendo D, Wang ZQ, Zhang CX, (2003) Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol Endocrinol 17: 1880-1892.
32. Crabtree JS, Scacheri PC, Ward JM, McNally SR, Swain GP, et al. (2003) Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol 23: 6075-6085.
33. Lu J, Herrera PL, Carreira C, Bonnavion R, Seigne C, et al. (2010) Alpha cell-specific Men1 ablation triggers the transdifferentiation of glucagon-expressing cells and insulinoma development. Gastroenterology 138: 1954-1965.
34. Wu X, Hua X, (2008) Menin, histone h3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective. Curr Mol Med 8: 805-815.
35. Furuta M, Yano H, Zhou A, Rouillé Y, Holst JJ, et al. (1997) Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci U S A 94: 6646-6651.
36. Hayashi Y, Yamamoto M, Mizoguchi H, Watanabe C, Ito R, et al. (2009) Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet alpha cells but not of intestinal L-cells. Mol Endocrinol 23: 1990-1999.
37. Chen M, Gavrilova O, Zhao WQ, Nguyen A, Lorenzo J, et al. (2005) Increased glucose tolerance and reduced adiposity in the absence of fasting hypoglycemia in mice with liver-specific Gs alpha deficiency. J Clin Invest 115: 3217-3227.
38. Ackermann AM, Gannon M, (2007) Molecular regulation of pancreatic beta-cell mass development, maintenance, and expansion. J Mol Endocrinol 38: 193-206.
39. Collombat P, Xu X, Ravassard P, Sosa-Pineda B, Dussaud S, et al. (2009) The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells. Cell 138: 449-462.
40. Kedees MH, Guz Y, Vuguin PM, Vargas C, Cui L, et al. (2007) Nestin expression in pancreatic endocrine and exocrine cells of mice lacking glucagon signaling. Dev Dyn 236: 1126-1133.
41. Webb GC, Akbar MS, Zhao C, Swift HH, Steiner DF, (2002) Glucagon replacement via micro-osmotic pump corrects hypoglycemia and alpha-cell hyperplasia in prohormoneconvertase 2 knockout mice. Diabetes 51: 398-405.
42. Gu W, Yan H, Winters KA, Komorowski R, Vonderfecht S, et al. (2009) Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther 331: 871-881.
43. Perren A, Anlauf M, Henopp T, Rudolph T, Schmitt A, et al. (2007) Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab 92: 1118-1128.
44. Anlauf M, Perren A, Kloppel G, (2007) Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology 74: 279-284.
45. Kloppel G, Anlauf M, Perren A, (2007) Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors. Endocr Pathol 18: 150-155.
46. Kimura W, Kuroda A, Morioka Y, (1991) Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. D ig Dis Sci 36: 933-942.
47. Conarello SL, Jiang G, Mu J, Li Z, Woods J, et al. (2007) Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 50: 142-150.
48. Umino Y, Everhart D, Solessio E, Cusato K, Pan JC, et al. (2006) Hypoglycemia leads to age-related loss of vision. Proc Natl Acad Sci U S A 103: 19541-19545.
49. Chesnokova V, Wong C, Zonis S, Gruszka A, Wawrowsky K, et al. (2009) Diminished pancreatic beta-cell mass in securin-null mice is caused by beta-cell apoptosis and senescence. Endocrinology 150: 2603-2610.